Peginterferon alfa-2a, Ribavirin, Amantadine — Competitive Intelligence Brief

Peginterferon alfa-2a, Ribavirin, Amantadine (Peginterferon alfa-2a, Ribavirin, Amantadine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination therapy. Area: Virology/Infectious Disease.

phase 3 Antiviral combination therapy Interferon-alpha receptor, viral RNA polymerase, viral M2 ion channel Virology/Infectious Disease Small molecule

Target snapshot

Peginterferon alfa-2a, Ribavirin, Amantadine (Peginterferon alfa-2a, Ribavirin, Amantadine) — University of Hamburg-Eppendorf. This triple-drug combination uses peginterferon alfa-2a and ribavirin as antivirals with immunomodulatory effects, plus amantadine as an additional antiviral agent, to suppress viral replication and enhance immune response.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Peginterferon alfa-2a, Ribavirin, Amantadine TARGET	Peginterferon alfa-2a, Ribavirin, Amantadine	University of Hamburg-Eppendorf	phase 3	Antiviral combination therapy	Interferon-alpha receptor, viral RNA polymerase, viral M2 ion channel
pegylated interferon alpha 2a, ribavirin	pegylated interferon alpha 2a, ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
D: Peg-interferon alpha-2a & Ribavirin	D: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
Peginterferon alfa-2a, Ribavirin, epoetin-β	Peginterferon alfa-2a, Ribavirin, epoetin-β	Germans Trias i Pujol Hospital	marketed	Antiviral combination therapy with hematopoietic agent	Interferon-α receptor; viral RNA polymerase; erythropoietin receptor
F: Peg-interferon alpha-2a & Ribavirin	F: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; Hepatitis C virus RNA-dependent RNA polymerase
Ribavirin, Peg interferon alfa 2b	Ribavirin, Peg interferon alfa 2b	Brooke Army Medical Center	marketed	Antiviral combination therapy	HCV RNA-dependent RNA polymerase; interferon-alpha receptor
Pegylated interferon and ribavirin	Pegylated interferon and ribavirin	Pacific Health Foundation	marketed	Antiviral combination therapy	Interferon-alpha receptor; Hepatitis C virus RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination therapy class)

1. Kaohsiung Medical University Chung-Ho Memorial Hospital · 6 drugs in this class
2. National Taiwan University Hospital · 6 drugs in this class
3. Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
4. Hepatitis Resource Network · 1 drug in this class
5. Hospices Civils de Lyon · 1 drug in this class
6. MTI Medical Private Limited, Pakistan · 1 drug in this class
7. Pacific Health Foundation · 1 drug in this class
8. RedHill Biopharma Limited · 1 drug in this class
9. Sherief Abd-Elsalam · 1 drug in this class
10. The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · 1 drug in this class